A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors.
Dejan Juric
Consultant or Advisory Role - Novartis
Jean-Charles Soria
No relevant relationships to disclose
Sunil Sharma
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Research Funding - Novartis
Udai Banerji
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Analia Azaro
No relevant relationships to disclose
Jayesh Desai
Consultant or Advisory Role - Novartis
Honoraria - Novartis
Francois Philippe Ringeisen
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Audrey Kaag
Employment or Leadership Position - Novartis
Rajkumar Radhakrishnan
Employment or Leadership Position - Novartis
Florence Hourcade-Potelleret
Employment or Leadership Position - Novartis
Heiko Maacke
Employment or Leadership Position - Novartis
Jordi Rodon Ahnert
No relevant relationships to disclose